Mp56-03 Oncological Outcomes for T1 Small Renal Cell Carcinoma After Partial Nephrectomy Is Not Significantly Associated With Histopathological Subtype: A 20-Year Retrospective Follow Up From One Single Institution

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy IV (MP56)1 May 2024MP56-03 ONCOLOGICAL OUTCOMES FOR T1 SMALL RENAL CELL CARCINOMA AFTER PARTIAL NEPHRECTOMY IS NOT SIGNIFICANTLY ASSOCIATED WITH HISTOPATHOLOGICAL SUBTYPE: A 20-YEAR RETROSPECTIVE FOLLOW UP FROM ONE SINGLE INSTITUTION Victor Sandoval, E. Lizabeth Ellis, Jesus Cendejas, Ashley Li, Srindhi Venkatesh, Thomas Osinski, Changyong Feng, Guan Wu, and William Tabayoyong Victor SandovalVictor Sandoval , E. Lizabeth EllisE. Lizabeth Ellis , Jesus CendejasJesus Cendejas , Ashley LiAshley Li , Srindhi VenkateshSrindhi Venkatesh , Thomas OsinskiThomas Osinski , Changyong FengChangyong Feng , Guan WuGuan Wu , and William TabayoyongWilliam Tabayoyong View All Author Informationhttps://doi.org/10.1097/01.JU.0001008940.44711.d4.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Patial Nephrectomy (PN) is the preferred surgical treatment for localized T1 Renal Cell Carcinoma. We determined oncological outcomes for T1 RCC categorized on histopathology at our institution. METHODS: We performed a retrospective analysis of PNs from 1997 to 2018. Demographic and clinical information was collected. Local recurrence and survival analysis were performed using Kaplan-Meier and Cox regression analyses. Separately, outcomes for those with Clear Cell (ccRCC), Papillary type 1(pRCC1), papillary type (pRCC2) and Chromophobe (chRCC) were analyzed. RESULTS: We identified 850 PNs at our institution with 537 patients having T1 RCC on final pathology. Table 1 contains pertinent demographic and clinical information for our cohort. Significant differences were found in age at surgery, local recurrence rate, mortality rate and cancer specific mortality between RCC subtypes and stage. Positive margin rate was 10.5% (64/572), but was not associated with recurrence or survival. On cox regression analysis age at surgery (HR 1.06, 95% CI 1.01-1.11, p=0.02) and recurrence (HR 4.9, 95% CI 1.9-13.1, p=0.01) was significant for death. Kaplan-Meier curves for recurrence and survival are shown in Figure 1. While there were significant differences in recurrence free survival and overall survival for T1a vs T1b RCCs, these differences were not found between RCC subtypes. CONCLUSIONS: For T1 tumors, RCC histologic subtype is not significantly associated with recurrence free or overall survival. Overall and cancer specific survival is excellent for those presenting for T1 RCC. Most mortality in this population is not caused by RCC. Furthermore, most local recurrences happen over 3 years from surgery and in those with T1b cancers. Thus, it may be beneficial to have less frequent but longer surveillance for those presenting with T1 RCC. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e926 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Victor Sandoval More articles by this author E. Lizabeth Ellis More articles by this author Jesus Cendejas More articles by this author Ashley Li More articles by this author Srindhi Venkatesh More articles by this author Thomas Osinski More articles by this author Changyong Feng More articles by this author Guan Wu More articles by this author William Tabayoyong More articles by this author Expand All Advertisement PDF downloadLoading ...